Urology
Volume 72, Issue 6 , Pages 1293-1297 , December 2008

Use of Nonsteroidal Anti-inflammatory Drugs After Radical Retropubic Prostatectomy: A Prospective, Randomized Trial

Received 26 September 2007 ,Accepted 5 December 2007.

References 

  1. Pereg D, Lishner M. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med. 2005;258:115–123
  2. Huang JJ, Taguchi A, Hsu H, et al. Preoperative oral rofecoxib does not decrease postoperative pain or morphine consumption in patients after radical prostatectomy: a prospective, randomised, double-blinded placebo-controlled trial. J Clin Anesth. 2001;13:94–97
  3. Nielsen JD, Holm-Nielsen A, Jespersen J, et al. The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy—a prospective, randomised, double-blind, placebo-controlled study. Scand J Urol Nephrol. 2000;34:194–198
  4. Ulshofer B, Dorst V, Kretschmer V, et al. Hemostaseological management of urological operations in patients taking aspirin using the Thrombostat 4000. Semin Thromb Hemost. 1995;21(suppl 2):52–58
  5. See WA, Fuller JR, Toner ML. An outcome study of patient-controlled analgesia, with or without ketorolac, following radical retropubic prostatectomy. J Urol. 1995;154:1429–1432
  6. Ala-Opas MY, Gronlund SS. Blood loss in long-term aspirin users undergoing transurethral prostatectomy. Scand J Urol Nephrol. 1996;30:203–206
  7. Gwirtz KH, Kim HC, Nagy DJ, et al. Intravenous ketorolac and subarachnoid opioid analgesia in the management of acute postoperative pain. Reg Anesth. 1995;20:395–401
  8. Webster TM, Herrell D, Chang SS, et al. Robotic assisted laparoscopic radical prostatectomy versus retropubic radical prostatectomy: a prospective assessment of postoperative pain. J Urol. 2005;174:912–914
  9. Grant EG, Gregory B, Moore S. Nurse evaluation of a pain medication protocol in a selective postoperative population. Urol Nurs. 1996;16:86–88
  10. Brown CR, Mazzulla JP, Mok MS, et al. Comparison of repeat doses of intramuscular ketorolac tromethamine and morphine sulfate for analgesia after major surgery. Pharmacotherapy. 1990;10(part 2):45S–50S
  11. Grass JA, Sakima NT, Valley M, et al. Assessment of ketorolac as an adjuvant to fentanyl patient-controlled epidural analgesia after radical retropubic prostatectomy. Anesthesiology. 1993;78:642–648discussion 21A
  12. Parker RK, Holtman B, White PF. Effect of ketorolac on the postoperative opioid requirement and recovery profile. Anesthesiology. 1991;75(suppl):A758
  13. Balestrieri P, Simmons G, Hill D, et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynaecologic abdominal surgery. J Clin Anesth. 1997;9:358–364
  14. Pieri M, Meacci L, Santini L, et al. Control of acute pain after major abdominal surgery in 585 patients given tramadol and ketorolac by intravenous infusion. Drugs Exp Clin Res. 2002;28:113–118
  15. Park M, Houck C, Sethna N, et al. Ketorolac suppresses postoperative bladder spasms after pediatric ureteral reimplantation. Anesth Analg. 2000;91:11–15
  16. Mikhailidis DP, Jeremy JY, Dandona P. Urinary bladder prostanoids: their synthesis, function and possible role in the pathogenesis and treatment of disease. J Urol. 1987;137:577–582
  17. Kanno T, Shibasaki N, Ito M, et al. Early catheter removal and postoperative status of bladder outflow after retropubic radical prostatectomy. Hinyokika Kiyo. 2004;50:773–777
  18. Palmer JS, Worwag EM, Conrad WG, et al. Same day surgery for radical retropubic prostatectomy: is it an attainable goal?. Urology. 1996;47:23–28
  19. Worwag E, Chodak GW. Overnight hospitalization after radical retropubic prostatectomy: the impact of two clinical pathways on patient satisfaction, length of hospitalization, and morbidity. Anesth Analg. 1998;87:62–67
  20. Habel LA, Zaho W, Stanford JL. Daily aspirin use and prostate cancer risk in a large multiracial cohort in the US. Cancer Causes Control. 2002;13:427–434
  21. Jacobs EJ, Rodriguez C, Mondul AM, et al. A large cohort study of aspirin and other non-steroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst. 2005;97:975–980
  22. Thun MJ, Henley SJ, Patrono C. Non-steroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. J Natl Cancer Inst. 2002;94:252–266

PII: S0090-4295(07)02611-8

doi: 10.1016/j.urology.2007.12.039

Urology
Volume 72, Issue 6 , Pages 1293-1297 , December 2008

Article Tools